Risk-Benefit of Asthma Therapy in Children: Topical Corticosteroids

摘要: Inhaled corticosteroids (ICS) are now considered the most effective asthma therapy, and first-line therapy for control of in both children adults [1– 4] . In past, ICS were mainly used with severe persistent asthma. Nowadays, they also recommended treatment mild to moderate asthma, countries, have become treatment, even very young [5] However, still fail enjoy a favorable reputation terms safety tolerability [6] Many patients (and parents) “steroid phobia” that is based on local systemic adverse events from high-dose or oral corticosteroids, leading poor compliance [7– 9] A number been developed made available treat over last 30 years. They include beclomethasone dipropionate (BDP), budesonide (BUD), fluticasone propionate (FP), triamcinolone acetonide (TA), flunisolide (FLUN), mometasone furoate (MF), ciclesonide (CIC) [10] Each has unique physiochemical properties confer distinct pharmacologic characteristics regarding potency, efficacy, safety, tolerability, lung deposition, receptor binding, lipophilicity, esterification (Table 1 ). children, best studied date BPD BUD [11] Therefore, many data references mentioned this chapter will be studies BUD. The newest (CIC), which asthmatic published [12] recently. recent study by Pedersen et al. concluded ciclesonide’s efficacy profile similar [13]